JP2022516086A5 - - Google Patents

Info

Publication number
JP2022516086A5
JP2022516086A5 JP2021537220A JP2021537220A JP2022516086A5 JP 2022516086 A5 JP2022516086 A5 JP 2022516086A5 JP 2021537220 A JP2021537220 A JP 2021537220A JP 2021537220 A JP2021537220 A JP 2021537220A JP 2022516086 A5 JP2022516086 A5 JP 2022516086A5
Authority
JP
Japan
Prior art keywords
fluorine
atom
compound according
atoms
chlorine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021537220A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022516086A (ja
Filing date
Publication date
Priority claimed from US16/235,543 external-priority patent/US10752593B2/en
Application filed filed Critical
Publication of JP2022516086A publication Critical patent/JP2022516086A/ja
Publication of JP2022516086A5 publication Critical patent/JP2022516086A5/ja
Withdrawn legal-status Critical Current

Links

JP2021537220A 2018-12-28 2019-12-27 神経網膜疾患の治療および/または予防における治療活性物質として使用するための化合物 Withdrawn JP2022516086A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16/235,543 2018-12-28
US16/235,543 US10752593B2 (en) 2018-12-28 2018-12-28 Compounds for use as therapeutically active substances in the treatment of retinal diseases
PCT/US2019/068759 WO2020140043A1 (en) 2018-12-28 2019-12-27 Compounds for use as therapeutically active substances in the treatment and/or prevention of neuroretinal diseases

Publications (2)

Publication Number Publication Date
JP2022516086A JP2022516086A (ja) 2022-02-24
JP2022516086A5 true JP2022516086A5 (enExample) 2022-11-30

Family

ID=69188012

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021537220A Withdrawn JP2022516086A (ja) 2018-12-28 2019-12-27 神経網膜疾患の治療および/または予防における治療活性物質として使用するための化合物

Country Status (15)

Country Link
US (1) US10752593B2 (enExample)
EP (1) EP3902606A1 (enExample)
JP (1) JP2022516086A (enExample)
KR (1) KR20210110849A (enExample)
CN (1) CN113301958A (enExample)
AU (1) AU2019414950A1 (enExample)
BR (1) BR112021011599A2 (enExample)
CA (1) CA3125278A1 (enExample)
CL (1) CL2021001725A1 (enExample)
EA (1) EA202191057A1 (enExample)
IL (1) IL284298A (enExample)
MX (1) MX2021007813A (enExample)
PH (1) PH12021551092A1 (enExample)
SG (1) SG11202104958UA (enExample)
WO (1) WO2020140043A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10807973B2 (en) 2018-12-28 2020-10-20 Endogena Therapeutics, Inc. Compounds for use as therapeutically active substances in the treatment of retinal diseases
AU2020454040B2 (en) 2020-06-19 2025-03-06 Endogena Therapeutics, Inc. New compounds and their use as therapeutically active substances in the treatment and/or prevention of diseases involving the retinal pigment epithelium

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6066675A (en) 1996-09-13 2000-05-23 The Regents Of The University Of California Method for treatment of retinal diseases
CA2216439A1 (en) 1996-09-25 1998-03-25 Derek Van Der Kooy Pharmaceuticals containing retinal stem cells
AU1920501A (en) 1999-12-03 2001-06-12 Alcon Universal Limited The use of caspase 9 inhibitors to treat ocular neural pathology
JP2011506445A (ja) 2007-12-13 2011-03-03 アムジエン・インコーポレーテツド γ−セクレターゼ調節剤
US9018202B2 (en) 2010-12-03 2015-04-28 Allergan, Inc. Methods for treating diseases of the retina
US20130046003A1 (en) 2011-07-22 2013-02-21 Mohammed I. Dibas Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating retinal diseases
WO2013029338A1 (en) 2011-09-01 2013-03-07 Glaxo Group Limited Novel compounds
WO2014079850A1 (en) 2012-11-23 2014-05-30 F. Hoffmann-La Roche Ag Substituted heterocyclic derivatives
DE102013110714A1 (de) 2013-09-27 2015-04-02 Eberhard Karls Universität Tübingen Medizinische Fakultät Prophylaxe und Behandlung einer nicht auf einer Proteinfaltungsstörung beruhenden neurodegenerativen Erkrankung
US12472157B2 (en) 2014-11-07 2025-11-18 Nacuity Pharmaceuticals, Inc. Treatment of retinitis pigmentosa with n-acetylcysteine amide

Similar Documents

Publication Publication Date Title
JP2020122957A5 (enExample)
JP2020534390A5 (enExample)
JP2019502701A5 (enExample)
JP2020118959A5 (enExample)
JP2016135874A5 (enExample)
JP2017534766A5 (enExample)
JP2008544458A5 (enExample)
JP1729863S (ja) 組立て遊戯具用ブロック
JP2023508938A5 (enExample)
JP2019180784A5 (enExample)
MX2021007505A (es) Síntesis de 3-metil-1,2,4-tiadiazol-5-carbohidrazida o de su forma deuterada con metil-d3.
JP2017141454A5 (enExample)
Miska Arithmetic properties of the sequence of derangements
JP2021530432A5 (enExample)
JP2008501844A5 (enExample)
CN113286798A (zh) 内环硫脒酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途
JP2020533431A5 (enExample)
CN309288676S (zh) 弹夹硬盘盒(proedge-ssd)
JP2022077370A5 (enExample)
CN309336607S (zh) 分体式软水机
CN309483554S (zh) 烧烤炉
CN309279211S (zh) 调料架
CN309159535S (zh) 高脚凳
CN309261613S (zh) 收纳架(单个款)
CN309237005S (zh) 灰铜硬箱